<DOC>
	<DOCNO>NCT00984139</DOCNO>
	<brief_summary>This phase IV open study evaluate persistence humoral antibody hepatitis B well immune response challenge dose hepatitis B vaccine adolescent age 12-13 year , receive three consecutive dos GSK Biologicals ' recombinant hepatitis B vaccine ( Engerix™-B ) infancy .</brief_summary>
	<brief_title>Persistence Immunity Against Hepatitis B 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Accepted representative ( LAR ( ) ) comply requirement protocol . A male female 12 13 year age time enrolment . With documented evidence previous vaccination three consecutive dos EngerixB Germany : first two dos receive 9 month age third dose receive 18 month age . Written inform consent obtain parent ( ) LAR ( ) subject time enrolment . Written inform assent obtain subject addition inform consent sign parent ( ) /LAR ( ) . Healthy subject establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Females childbearing potential time study entry must negative pregnancy test prior administration dose vaccine require abstinent use adequate contraceptive precaution one month prior vaccination . Subjects require agree continue precaution two month vaccination . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Evidence previous hepatitis B booster vaccination since administration third dose EngerixB vaccine . History hepatitis B disease . Hepatitis B vaccination birth . Adolescents live institutional care . Planned administration /administration vaccine foreseen study protocol period start 30 day HBV vaccine challenge end 30 day . Administration immunoglobulins and/or blood product within three month precede HBV vaccine challenge plan administration study period . Chronic administration immunosuppressant immunemodifying drug within six month prior HBV vaccine challenge.. Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Use investigational nonregistered product study vaccine within 30 day precede challenge dose study vaccine , plan use study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . Known hypersensitivity component HBV vaccine evidence hypersensitivity previous immunisation vaccine contain hepatitis B component . Acute disease and/or fever time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>persistence</keyword>
	<keyword>HBV</keyword>
	<keyword>Long-term</keyword>
	<keyword>Engerix™-B Kinder</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>adolescent</keyword>
</DOC>